Non-esterified fatty acids and the liver: why is insulin secreted into the portal vein?

Aims/hypothesis. Insulin control of glucose output is a major mechanism by which appropriate amounts of glucose are produced to supply energy to the central nervous system, without causing long-term increases of the plasma glucose concentration. It is hypothesised that the primary route by which insulin maintains control over glucose production is indirect and is mediated by regulation of non-esterified fatty acid release from the adipocyte. The question arises as to why evolution has chosen insulin to be secreted into the portal vein, if control of the liver is partially or primarily indirect. It is suggested that alterations in hepatic insulin clearance which attend increases in central adiposity are an important part of the compensation for insulin resistance and limit the necessity for up-regulation of insulin secretion in insulin resistance secondary to central adiposity.¶Methods. Review of research from author's group and other laboratories.¶Results. Data over the previous decade indicate that suppression of glucose output by increased insulin is a relatively slow process, much slower than the rate of binding of insulin to hepatocytes. One explanation is that insulin acts on an extrahepatic tissue, which in turn alters a signal to the liver, reducing glucose output. Additional evidence for an extrahepatic primary effect of insulin emerges from experiments in which insulin was given portally or peripherally at half the portal dose. Endogenous glucose production was related to systemic, not portal insulin, supporting the concept that the primary step in insulin's action on liver is on some other tissue, altering signalling to the liver itself. Strong correlation between plasma non-esterified fatty acids (NEFA) and liver glucose output suggests that the primary effect is on the adipocyte. The primacy of the adipocyte locus for the insulin effect included data that insulin's action on liver is prevented when plasma NEFA are maintained, as well as data showing proportional decline in glucose production and fatty acids when antilipolysis is induced by an adenosine agonist.¶Why then, from an evolutionary point of view is insulin secreted into the portal vein? Institution of central adiposity in dogs with fat feeding causes hepatic insulin resistance, at least partially due to the provision of NEFA in portal blood. The initial response to resistance is enhanced beta-cell sensitivity to glucose; a secondary compensation is, however, a substantial reduction in liver clearance, allowing for a greater proportion of secreted insulin to reach muscle, where it can more efficiently stimulate glucose utilisation.¶Conclusion/interpretation. Non-esterified fatty acids act as a signal as well as a metabolic substrate. They can regulate glucose utilisation in muscle and apparently are important signals to the liver and the beta cells as well. The importance of portal vein NEFA concentrations to the function of the liver could explain insulin resistance of the liver with central pattern obesity. [Diabetologia (2000) 43: 946–952]

[1]  B. Zinman,et al.  Hepatic Glucose Production Is Regulated Both by Direct Hepatic and Extrahepatic Effects of Insulin in Humans , 1996, Diabetes.

[2]  Role of Insulin Resistance in Human Disease , 1997 .

[3]  J. McGarry,et al.  Fatty acids, lipotoxicity and insulin secretion , 1999, Diabetologia.

[4]  R N Bergman,et al.  Low insulin sensitivity is associated with clustering of cardiovascular disease risk factors. , 1997, American journal of epidemiology.

[5]  N. Barzilai,et al.  Carbon Flux via the Pentose Phosphate Pathway Regulates the Hepatic Expression of the Glucose-6-phosphatase and Phosphoenolpyruvate Carboxykinase Genes in Conscious Rats* , 1998, The Journal of Biological Chemistry.

[6]  R. Levine,et al.  The Relation of Insulin to Liver Metabolism , 1956, Diabetes.

[7]  J. Olefsky,et al.  Thiazolidinediones in the Treatment of Insulin Resistance and Type II Diabetes , 1996, Diabetes.

[8]  M Vranic,et al.  Glucagon enhances the direct suppressive effect of insulin on hepatic glucose production in humans. , 1997, The American journal of physiology.

[9]  R. Bergman Toward Physiological Understanding of Glucose Tolerance: Minimal-Model Approach , 1989, Diabetes.

[10]  R N Bergman,et al.  Dynamics of Hepatic and Peripheral Insulin Effects Suggest Common Rate-Limiting Step In Vivo , 1993, Diabetes.

[11]  R. Bergman,et al.  Peripheral effects of insulin dominate suppression of fasting hepatic glucose production. , 1990, The American journal of physiology.

[12]  R. Bergman New concepts in extracellular signaling for insulin action: the single gateway hypothesis. , 1997, Recent progress in hormone research.

[13]  T. Buchanan,et al.  Effect of Troglitazone on Insulin Sensitivity and Pancreatic β-Cell Function in Women at High Risk for NIDDM , 1996, Diabetes.

[14]  D L Rothman,et al.  Effects of free fatty acids on glucose transport and IRS-1-associated phosphatidylinositol 3-kinase activity. , 1999, The Journal of clinical investigation.

[15]  R. Bergman,et al.  Inhibition of lipolysis causes suppression of endogenous glucose production independent of changes in insulin. , 2000, American journal of physiology. Endocrinology and metabolism.

[16]  W. Glinsmann,et al.  Intrinsic regulation of glucose output by rat liver. , 1969, The American journal of physiology.

[17]  William Francis Ganong,et al.  Review of Medical Physiology , 1969 .

[18]  C. Park,et al.  Control of gluconeogenesis in liver. IV. Differential effects of fatty acids and glucagon on ketogenesis and gluconeogenesis in the perfused rat liver. , 1969, The Journal of biological chemistry.

[19]  G. Boden,et al.  The effects of free fatty acids on gluconeogenesis and glycogenolysis in normal subjects. , 1999, The Journal of clinical investigation.

[20]  A. Baron,et al.  Use of a variable tracer infusion method to determine glucose turnover in humans. , 1990, The American journal of physiology.

[21]  M. Vranic,et al.  Importance of peripheral insulin levels for insulin-induced suppression of glucose production in depancreatized dogs. , 1992, The Journal of clinical investigation.

[22]  R. Rizza,et al.  The effects of non-insulin-dependent diabetes mellitus on the kinetics of onset of insulin action in hepatic and extrahepatic tissues. , 1995, The Journal of clinical investigation.

[23]  P. Björntorp,et al.  Fatty acids in the portal vein of the rat regulate hepatic insulin clearance. , 1991, The Journal of clinical investigation.

[24]  H. Halkin,et al.  Hyperinsulinemia. A link between hypertension obesity and glucose intolerance. , 1985, The Journal of clinical investigation.

[25]  R. Bergman,et al.  Free Fatty Acid as a Link in the Regulation of Hepatic Glucose Output by Peripheral Insulin , 1995, Diabetes.

[26]  K. Petersen,et al.  Mechanism of free fatty acid-induced insulin resistance in humans. , 1996, The Journal of clinical investigation.

[27]  R N Bergman,et al.  Role of Glucose Effectiveness in the Determination of Glucose Tolerance , 1996, Diabetes Care.

[28]  Claudio Cobelli,et al.  Physiologic Evaluation of Factors Controlling , 1981 .

[29]  I. Jensen,et al.  Scintigraphic studies in rats. Kinetics of insulin analogues covering wide range of receptor affinities. , 1991, Diabetes.

[30]  D. Hems,et al.  Control of hepatic glycogenolysis. , 1980, Physiological reviews.

[31]  G. Reaven Role of Insulin Resistance in Human Disease , 1988, Diabetes.

[32]  H. Yki-Järvinen,et al.  No Reduction in Total Hepatic Glucose Output by Inhibition of Gluconeogenesis With Ethanol in NIDDM Patients , 1991, Diabetes.

[33]  R. N. Bergman,et al.  Role of glucose and insulin resistance in development of type 2 diabetes mellitus: results of a 25-year follow-up study , 1992, The Lancet.

[34]  A Mari,et al.  Free fatty acids impair hepatic insulin extraction in vivo. , 1999, Diabetes.

[35]  D. Chisholm,et al.  The metabolically obese, normal-weight individual revisited. , 1998, Diabetes.

[36]  J. Clore,et al.  Evidence for Dual Control Mechanism Regulating Hepatic Glucose Output in Nondiabetic Men , 1991, Diabetes.

[37]  H G Hers,et al.  Gluconeogenesis and related aspects of glycolysis. , 1983, Annual review of biochemistry.

[38]  M. Vranic,et al.  Resistance to insulin's acute direct hepatic effect in suppressing steady-state glucose production in individuals with type 2 diabetes. , 1999, Diabetes.

[39]  R. Bergman,et al.  Longitudinal Compensation for Fat-induced Insulin Resistance Includes Reduced Insulin Clearance and Enhanced ␤-cell Response Research Design and Methods , 2022 .

[40]  R. Rizza,et al.  Assessment of insulin action in insulin-dependent diabetes mellitus using [6(14)C]glucose, [3(3)H]glucose, and [2(3)H]glucose. Differences in the apparent pattern of insulin resistance depending on the isotope used. , 1986, The Journal of clinical investigation.

[41]  R. Bergman,et al.  Indirect effect of insulin to suppress endogenous glucose production is dominant, even with hyperglucagonemia. , 1997, The Journal of clinical investigation.

[42]  M. Vranic,et al.  Fatty Acids Mediate the Acute Extrahepatic Effects of Insulin on Hepatic Glucose Production in Humans , 1997, Diabetes.

[43]  J. Olefsky,et al.  In vivo kinetics of insulin action on peripheral glucose disposal and hepatic glucose output in normal and obese subjects. , 1986, The Journal of clinical investigation.

[44]  L. Mandarino,et al.  Dose-response characteristics for effects of insulin on production and utilization of glucose in man. , 1981, The American journal of physiology.

[45]  M. Vranic,et al.  Normal hepatic insulin sensitivity in lean, mild noninsulin-dependent diabetic patients. , 1996, The Journal of clinical endocrinology and metabolism.

[46]  J. Sturis,et al.  Alterations in the kinetics of C-peptide and insulin secretion in hyperthyroidism. , 1993, The Journal of clinical endocrinology and metabolism.

[47]  R N Bergman,et al.  Estimation of Endogenous Glucose Production During Hyperinsulinemic-Euglycemic Glucose Clamps: Comparison of Unlabeled and Labeled Exogenous Glucose Infusates , 1987, Diabetes.

[48]  R. Bergman,et al.  Modeling Error and Apparent Isotope Discrimination Confound Estimation of Endogenous Glucose Production During Euglycemic Glucose Clamps , 1988, Diabetes.

[49]  R. Rizza,et al.  Effects of Hyperglycemia on Glucose Production and Utilization in Humans: Measurement With [23H]-, [33H]-, and [614C]Glucose , 1986, Diabetes.

[50]  R. Bergman,et al.  Causal linkage between insulin suppression of lipolysis and suppression of liver glucose output in dogs. , 1996, The Journal of clinical investigation.

[51]  R. Rizza,et al.  Underestimation of Glucose Turnover Measured With [6-3H]- and [6,6-2 H2]- but not [6-14C]glucose During Hyperinsulinemia in Humans , 1989, Diabetes.

[52]  J. Auwerx,et al.  PPARgamma activators improve glucose homeostasis by stimulating fatty acid uptake in the adipocytes. , 1998, Atherosclerosis.